Literature DB >> 20335650

The one-two punch: knocking out angiotensin II in the heart.

Daniela Zablocki1, Junichi Sadoshima.   

Abstract

Ang II plays an important role in the pathophysiology of cardiovascular disease. Angiotensin-converting enzyme (ACE) inhibitors lower Ang II levels by inhibiting conversion of Ang I to Ang II, but Ang II levels have been shown to return to normal with chronic ACE inhibitor treatment. In this issue of the JCI, Wei et al. show that ACE inhibition induces an increase in chymase activity in cardiac interstitial fluid, providing an alternate pathway for Ang II generation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335650      PMCID: PMC2846074          DOI: 10.1172/JCI42644

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  The renin-angiotensin system in the twenty-first century.

Authors:  M G Nicholls; J I Robertson; T Inagami
Journal:  Blood Press       Date:  2001       Impact factor: 2.835

Review 2.  Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases.

Authors:  Louis J Dell'Italia; Ahsan Husain
Journal:  Curr Opin Cardiol       Date:  2002-07       Impact factor: 2.161

3.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.

Authors:  H Urata; A Kinoshita; K S Misono; F M Bumpus; A Husain
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

4.  Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.

Authors:  Chih-Chang Wei; Carlos M Ferrario; K Bridget Brosnihan; Diane M Farrell; Wayne E Bradley; Ayad A Jaffa; Louis J Dell'Italia
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

Review 5.  Pathways for bradykinin formation and inflammatory disease.

Authors:  Allen P Kaplan; Kusumam Joseph; Michael Silverberg
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

6.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

7.  Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

Authors:  J Biollaz; H R Brunner; I Gavras; B Waeber; H Gavras
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

8.  Angiotensin-converting enzyme 2 is an essential regulator of heart function.

Authors:  Michael A Crackower; Renu Sarao; Gavin Y Oudit; Chana Yagil; Ivona Kozieradzki; Sam E Scanga; Antonio J Oliveira-dos-Santos; Joan da Costa; Liyong Zhang; York Pei; James Scholey; Carlos M Ferrario; Armen S Manoukian; Mark C Chappell; Peter H Backx; Yoram Yagil; Josef M Penninger
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

9.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

10.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Authors:  John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

View more
  2 in total

Review 1.  Cardiac remodelling and RAS inhibition.

Authors:  Carlos M Ferrario
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-04-21

2.  CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy.

Authors:  Anthony J Valente; Robert A Clark; Jalahalli M Siddesha; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2012-04-26       Impact factor: 5.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.